FDA Approves New Hepatitis C Treatment

The U.S. Food and Drug Administration on Nov. 22 announced the approval of Olysio (simeprevir) to treat chronic hepatitis C virus infection.

The U.S. Food and Drug Administration has approved Olysio (simeprevir) for treatment of chronic hepatitis C virus infection, a disease that can lead to diminished liver function or liver failure. Most people infected with the virus have no symptoms of the disease until liver damage becomes apparent, which may take several years, and most of them then develop chronic hepatitis C. Some will develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice, infections. or liver cancer.

According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.

Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen and is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection or for whom previous treatment has not been effective, according to FDA's announcement.

"Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease," said Dr. Edward Cox, M.D., director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. The others, approved in 2011, are Victrelis (boceprevir) and Incivek (telaprevir).

Olysio was reviewed under FDA's priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists or offer significant improvement compared to available therapies.

Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J.; Victrelis is marketed by Whitehouse Station, N.J.-based Merck; and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.

Product Showcase

  • Matrix's OmniPro Vision AI Collision Avoidance System

    OmniPro Vision AI is a state-of-the-art collision avoidance system that features NIOSH award-winning Visual Artificial Intelligence (AI) technology. This highly accurate, powerful system identifies and alerts on pedestrians, vehicles and specified objects, ensuring safer facilities, mining operations and industrial sites. With its web-based cloud application, OmniPro Vision AI also logs and analyzes a wide range of data related to zone breach notifications. Operating without needing personal wearable devices or tags, OmniPro has visual and audible zone breach alerts for both operators and pedestrians. Read More

  • Magid® D-ROC® GPD412 21G Ultra-Thin Polyurethane Palm Coated Work Gloves

    Magid’s 21G line is more than just a 21-gauge glove, it’s a revolutionary knitting technology paired with an advanced selection of innovative fibers to create the ultimate in lightweight cut protection. The latest offering in our 21G line provides ANSI A4 cut resistance with unparalleled dexterity and extreme comfort that no other 21-gauge glove on the market can offer! Read More

  • Preventative Heat Safety

    Dehydration and heat exposure impair physical and cognitive performance. Proper hydration boosts heat stress resilience, but hydration needs are highly individualized and hard to predict across a workforce. Connected Hydration® empowers industrial athletes to stay safe through behavioral interventions, informed by sports science, and equips safety teams with critical insights to anticipate high-risk situations and adapt to evolving environmental factors. Curious about applying the latest in sports science based hydration strategies for industrial athletes? Stop by booth #1112 at AIHA or schedule a free demo today at https://epcr.cc/demo. Read More

Featured